站内搜索
最新录用更多>>
抗结核药物研究进展
投稿时间:2019-10-17  修订日期:2020-01-13  点此下载全文
引用本文:
摘要点击次数: 32
全文下载次数: 0
作者单位E-mail
韦媛媛 华东师范大学 18516611936@163.com 
基金项目:国家自然科学基金项目(面上项目,重点项目,重大项目)
中文摘要:近年来,随着结核病耐药频率不断升高,结核病治疗面临严峻的挑战,因此新型抗结核药物的研发显得尤为重要,并受到广泛关注。在过去十年中,抗结核药物的研发取得了重要进展,贝达喹啉、德拉马尼和普托马尼先后被批准上市,另外还有许多药物以及联合用药方案正在进行临床试验。本文将对近年来被批准用于临床和正在进行临床试验的新化学实体按靶点进行分类,并综述其作用机制、体内外药理活性、药代动力学性质以及临床研究结果。这些具有新靶点、新机制的药物为结核治疗开拓了新的前景,给多药耐药、广泛耐药结核病患者带来了希望。
中文关键词:抗结核新化学实体  作用机制  临床研究
 
Advances in anti-tuberculosis drugs
Abstract:Tuberculosis (TB) treatment is currently falling into a gigantic dilemma -particularly with the more and more frequent TB resistance, so the development of new anti-tuberculosis drugs is imperative and has received extensive attention. In the past decade, significant progress has been made in this field. Bedaquiline, Delamanid and Pretomanid have been approved for clinical use. In addition, many other drugs and combination protocols are undergoing clinical trials. This review focuses on the new chemical entities for TB treatments from multiple perspectives, including the mechanisms of action, in vitro and in vivo pharmacological activities, pharmacokinetic properties and clinical results. These drugs with new targets or mechanisms open up promising prospects for the treatment of tuberculosis, especially bringing hope to patients with multi-drug resistance tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB).
keywords:anti-tuberculosis new chemical entity  mechanism of action  clinical research
  查看/发表评论  下载PDF阅读器
相关附件:   介绍信  基金项目证明  附件1  附件2  20191228修订版  退修意见回复1228  退修意见回复0106  退修意见回复20200110  退修意见回复20200113
分享按钮